4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Monte Rosa Therapeutics, Inc. (GLUE) operates in the Biotechnology industry and is headquartered in Boston, United States with about 187 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, GLUE reported $124M in revenue.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Interactive charts & full statements → Open the GLUE valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $124M | $76M | $0M | $0M | — |
| Operating Income (EBIT) | ($54M) | ($81M) | ($143M) | ($112M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $4M | $3M | $13M | $23M | $85M |
| Operating Income (EBIT) | ($50M) | ($50M) | ($33M) | ($16M) | $44M |
| Net Income | ($44M) | ($46M) | ($27M) | ($12M) | $47M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $449M | $439M | $304M | $342M | — |
| Total Liabilities | $216M | $216M | $124M | $71M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GLUE viewer.
About TickerBase · Data methodology & sources